FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

First Drug Approved in New Class of Non-Opioid Pain Medicines; Agency Continues to Take Steps to Support New Approaches for Pain Management SILVER SPRING, Md., Jan. 30, 2025 /PRNewswire/ — Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral…